Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Overweight rating on Halozyme Therapeutics and raises the price target from $60 to $61.
August 10, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Halozyme Therapeutics and raises the price target from $60 to $61, which could positively impact the stock.
The raised price target by Morgan Stanley indicates a positive outlook for Halozyme Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100